TY - JOUR
T1 - The economic value of reducing mortality due to noncommunicable diseases and injuries
AU - Verguet, Stéphane
AU - Bolongaita, Sarah
AU - Chang, Angela Y.
AU - Cardoso, Diego S.
AU - Stevens, Gretchen A.
N1 - We thank the World Bank\u2019s Healthy Longevity Initiative (HLI) for funding. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the paper. S.V. acknowledges funding support from the Trond Mohn Foundation and NORAD through Bergen Centre for Ethics and Priority Setting (project number 813596). We received valuable comments from G. Alleyne, S. Al Tuwaijri, B. Essue, G. Garcia, P. Isenman, D. Jamison, P. Jha, U. Ram, S. Saadat and J. Veillard and participants from workshop meetings of the HLI (Mexico City, May 2022; Washington DC, October 2022), the Health Systems Research Symposium (Bogot\u00E1, November 2022) and the International Health Economics Association meeting (Cape Town, July 2023). An earlier version of the paper was published as part of the Compendium of Research for the World Bank\u2019s HLI.
PY - 2024/11
Y1 - 2024/11
N2 - With population aging, national health systems face difficult trade-offs in allocating resources. The World Bank launched the Healthy Longevity Initiative to generate evidence for investing in policies that can improve healthy longevity and human capital. As part of this initiative, we quantified the economic value of reducing avoidable mortality from major noncommunicable diseases and injuries. We estimated avoidable mortality—the difference between lowest-achieved mortality frontiers and projected mortality trajectories—for each cause of death, for 2000, 2019 and 2050, and for geographic regions, with high-income countries, India and China considered separately; we applied economic values to these estimates. The economic value of reducing cardiovascular disease avoidable mortality would be large for both sexes in all regions, reaching 2–8% of annual income in 2019. For cancers, it would be 5–6% of annual income in high-income countries and China, and for injuries, it would be around 5% in sub-Saharan Africa and Latin America and the Caribbean. Despite the large uncertainty surrounding our estimates, we offer economic values for reducing avoidable mortality by cause and metrics comparable to annual incomes, which enable multisectoral priority setting and are relevant for high-level policy discussions around budget and resource allocations.
AB - With population aging, national health systems face difficult trade-offs in allocating resources. The World Bank launched the Healthy Longevity Initiative to generate evidence for investing in policies that can improve healthy longevity and human capital. As part of this initiative, we quantified the economic value of reducing avoidable mortality from major noncommunicable diseases and injuries. We estimated avoidable mortality—the difference between lowest-achieved mortality frontiers and projected mortality trajectories—for each cause of death, for 2000, 2019 and 2050, and for geographic regions, with high-income countries, India and China considered separately; we applied economic values to these estimates. The economic value of reducing cardiovascular disease avoidable mortality would be large for both sexes in all regions, reaching 2–8% of annual income in 2019. For cancers, it would be 5–6% of annual income in high-income countries and China, and for injuries, it would be around 5% in sub-Saharan Africa and Latin America and the Caribbean. Despite the large uncertainty surrounding our estimates, we offer economic values for reducing avoidable mortality by cause and metrics comparable to annual incomes, which enable multisectoral priority setting and are relevant for high-level policy discussions around budget and resource allocations.
UR - http://www.scopus.com/inward/record.url?scp=85205057888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205057888&partnerID=8YFLogxK
U2 - 10.1038/s41591-024-03248-4
DO - 10.1038/s41591-024-03248-4
M3 - Article
C2 - 39333314
AN - SCOPUS:85205057888
SN - 1078-8956
VL - 30
SP - 3335
EP - 3344
JO - Nature Medicine
JF - Nature Medicine
IS - 11
ER -